title: Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
authors.forename: E
authors.initials: E
authors.lastname: Griessinger
authors.forename: C
authors.initials: C
authors.lastname: Frelin
authors.forename: N
authors.initials: N
authors.lastname: Cuburu
authors.forename: V
authors.initials: V
authors.lastname: Imbert
authors.forename: C
authors.initials: C
authors.lastname: Dageville
authors.forename: M
authors.initials: M
authors.lastname: Hummelsberger
authors.forename: N
authors.initials: N
authors.lastname: Sirvent
authors.forename: M
authors.initials: M
authors.lastname: Dreano
authors.forename: J-F
authors.initials: JF
authors.lastname: Peyron
mesh_terms: D000818:Animals; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology*; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors*
chemical_list: C519899:AS602868; D016328:NF-kappa B; D011743:Pyrimidines; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3